Menu

Infographic: Brain Infection and Alzheimer’s Disease Pathology

Emerging evidence links bacterial or viral infection with the neuropathology of Alzheimer’s disease.

Aug 31, 2017
Jill U. Adams

© KIMBERLY BATTISTA

Numerous studies on postmortem brains have found evidence of infection, such as biofilms, in the same regions as Alzheimer’s neurodegeneration—namely, the hippocampus and temporal lobe (1). There are  some data that suggest the pathogens themselves can produce amyloid precursor protein (APP), which is processed into amyloid-β by the cell (2). More commonly, researchers have blamed the innate immune system—triggered by the pathogens once they enter the brain—for Alzheimer’s pathology. The activation of Toll-like receptor 2, for example, triggers the release of proinflammatory cytokines by microglial cells (3). These immune responses help protect brain from the infection, but they can also cause collateral damage—such as the death of nearby neurons. In addition, amyloid-β, produced by nearby neurons, may be an antimicrobial peptide that gets recruited to fight the pathogen; the peptide surrounds and seals off the pathogen (4). Some pathogens form a biofilm that is impenetrable to the immune system. Alternatively, some researchers think that infection affects neural processing of APP, leading to an overproduction and then aggregation of amyloid-β (5), a telltale sign of Alzheimer’s disease.

© KIMBERLY BATTISTA

Read the full story.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!